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1.
Introduction 2 diabetes and IFG. As a result of their low resolution the 48 diagnosis can occur very late in the aetiology of the disease, 49 and after some physiological damage has occurred [19, 20] .
50
Combined with incomplete compliance with regular medical 51 checks, many individuals in at-risk groups can go undiagnosed 52 for several years [21, 20] .
53
This research engineers a new model-based insulin sen-54 sitivity test, relying on the dynamic state after a low-dose 55 glucose and insulin input. During this transient state, the 56 metabolic system model employed has been shown to be 57 highly correlated (r = 0.97) to the clamp test [22, 23] 
Methodology

Procedure
76
The simulation procedure used in this study is shown in the 77 schematic in Fig. 1 , and explained in more detail in the follow- ing sections:
79
(1) Insulin sensitivity from 146 euglycaemic-hyperinsulinae-80 mic clamp tests [24] is calculated from the test data (ISI).
81
(2) A virtual cohort is created by fitting the metabolic model 
Test protocol
98
The test is designed to be a short dynamic test to assess 99 insulin sensitivity from a metabolic system model fit to the 100 transient plasma glucose and insulin curves after intravenous 101 (IV) bolus injections of glucose and insulin. The model then 102 relates interstitial insulin to plasma glucose to determine the 103 subject's sensitivity to insulin. The protocol has to account 104 for a wide variety of individuals (lean, obese, insulin resis-105 tant, diabetic) and be short, robust and simple enough to be 106 applicable in a clinical setting. The dosing should be lower 107 than in an IVGTT to assess a more physiological state and 108 to minimise regulatory responses, such as suppression of 109 endogenous glucose production (EGP) and pancreatic insulin 110 secretion.
111
The protocol used in this development study results in 112 metabolic dose-response curves as shown for glucose and 113 insulin in the example in Fig. 2 . It is 55 min long and includes: 114
(1) Inject a fixed dose of glucose (5, 10 or 20 g) at 0 min.
115
(2) Inject a fixed dose of insulin (0.5, 1 or 2 U) at 10 min. 
117
(4) Fit metabolic models of glucose, insulin and C-peptide to 118 dose-response curves.
119
(5) Determine insulin sensitivity from model parameter S I .
120
A more frequent sampling directly after the injections, as 121 done in an IVGTT is not practicable, as the mixing process 122 in plasma can take up to 5-8 min to complete, and earlier 123 measurements may thus be inaccurate [25] .
124
The dosing of 10 g of glucose and 1 U of insulin was chosen 125 as it is physiological and minimises the risk of hypoglycaemia.
126
It is also large enough to provide a good signal to noise ratio.
127
The protocol was also simulated with half (5 g glucose/0.5 U 128 insulin) and twice (20 g glucose/2 U insulin) the dose to assess care unit (ICU) data [26] , in glycaemic control trials in criti-137 cal care [27] [28] [29] [30] and on euglycaemic-hyperinsulinaemic clamp 138 and IVGTT data on healthy, insulin resistant and type 2 dia-139 betes subjects [22, 31] . To account for metabolic differences 140 between critically ill and healthy subjects, a time-varying 141 insulin sensitivity parameter was employed in validations on 142 critically ill subjects. On non-ICU populations, this correc-143 tion was not necessary and the model was able to accurately 144 account for all dynamics [22, 31] .
145
The glucose-insulin pharmacodynamic model is derived 146 from the Minimal Model by Bergman et al. [6] . This model is 147 further enhanced by glucose clearance saturation dynamics 148 in the form of a Michaelis-Menten equation [32, 33] .
149
The two compartment insulin pharmacokinetics model 150 used here is the primary enhancement from the original sys-151 tem model. It is derived from earlier studies by Sherwin et al. 152 [34]. The accessible central compartment can be understood as 153 plasma plus fast exchanging tissues. The peripheral compart-154 ment represents interstitial fluid. The model accounts for the 155 major losses of insulin from the central compartment by the 156 liver and the kidneys and the loss out of the peripheral com-157 partment, mainly insulin binding and eventual degradation by 158 the cells. Transport between the compartments is assumed 159 to be bi-directional diffusion. The resulting system model is 160 defined by the following equations [31] : 
212
The remaining parameters, n L and x for insulin and S I 213 and V G for glucose are identified using the integral based 214 fitting method described in more detail by Hann et al. [26] .
215
Briefly, the differential equations are integrated in different 216 time-steps by interpolating between discrete measurements, 217 transforming the non-convex non-linear problem into a set of 218 linear equations that can be easily solved using linear least 219 squares (LS). The method is convex and not starting point 220 dependent, unlike commonly used non-linear recursive least 221 squares (NRLS). Errors in the integration of equations, i.e. due 222 to noise, are not critical, as the method minimises areas under 223 the curve, not absolute differences, thus effectively filtering 224 noisy data [26, 43] . The errors have been shown to be, in the 225 limit, on the order of model error [26] . Integrating Eq.
(1) in the 226 interval [t 0 , t 1 ] yields:
The same method is applied to the measured plasma 234 insulin profile I(t) to estimate parameters n L and x, using the 235 analytical solution for Q(t) in integrating Eq. (3).
The result is a set of linear equations:
The time intervals used in the integrations can be chosen 240 to suit the available data density, as long as the minimum 241 number of intervals required are used to ensure an optimal 242 LS solution [26] . In this study, two sets of measured data are 243 available (I(t) and G(t)) to estimate two parameters in each. 244 The optimal interval length was identified as 2 min in this 245 study, resulting in 28 integral equation for each data set. No 246 additional weighting or normalisation was performed with the 247 equations. (ISI = P ss /I ss ).
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The clamp trials were fitted by the model described in 6.4%) for insulin [22] . are subsequently identified from the test profiles as described 300 in Section 2.4.
301
Model simulation parameters determined from the clamp 302 population as described in Sections 2.4 and 2.5 are given in 303 Table 2 . These parameter values are used to create the virtual 304 cohort on which the test protocol is simulated.
305
Pancreatic insulin secretion is not known for this cohort, as 306 C-peptide data is not available. A healthy pancreas responds 307 to a glucose input by secreting insulin in two phases. The 308 first phase consists of an insulin burst, lasting approxi-309 mately 10 min, followed by a second phase of lower dose, 310 but longer duration [35] . Insulin secretion can be suppressed 311 or reduced by exogenous insulin, with a full suppression 312 only achievable by a prolonged infusion of large amounts of 313 insulin [3]. In the protocol for this study, an insulin bolus is 314 injected 10 min after glucose, thus not affecting first phase 315 burst, but suppressing second phase insulin secretion. Sim-316 ulated total insulin secretion rate is thus reduced back to 317 its basal rate after the bolus injection of exogenous insulin 318 [23, 48, 49] .
319
Pre-hepatic endogenous insulin secretion can be simu-320 lated by a basal secretion rate, superimposed by a first-phase 321 burst. The burst peaks at a rate of 72 mU min −1 m −2 BSA [50,51], 322 which is dependent on body surface area (BSA), and is fol-323 lowed by an exponential decay lasting 10 min. For the lower 324 and higher dose protocol, this first-phase burst is halved and 325 doubled, respectively [52] . Basal endogenous secretion u b is 326 calculated from the steady state fasting insulin balance using 327 Eq. (3) with insulin concentrations I b and Q b = (3/5)I b , and a 328 
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( 2 0 0 7 ) xxx-xxx randomly generated first pass hepatic extraction x: The maximal suppression at the 10 g/1 U dose was chosen 381 randomly from a normal distribution between 25 and 75%. 382 For the lower (5 g/0.5 U) and higher (20 g/2 U) dose variants, 383 EGP suppr was shifted to 0-50 and 50-100%, respectively. Stud-384 ies have shown a direct dose-dependent relationship between 385 glucose concentration and suppression of EGP [57] , validating 386 this basic approach.
387
The random disturbances thus assumed in this Monte 388 Carlo analysis are:
389
• Glucose assay errors: CV intra = 1%; CV inter = 2% [18] 
390
• Insulin assay errors: CV intra = 2%; CV inter = 2.8% [18, 60] The required number of Monte Carlo simulations was iden-399 tified to be 500 in a convergence test, as the variability in the 400 standard deviation (S.D.) of the resulting S I value identified did 401 not change significantly with more runs.
402
An example of the resulting simulated profiles of glucose 403 and insulin responses during the proposed test, employing all 404 three dosing options on one virtual subject, is shown in Fig. 2 
Results
The Note that the ∼ 60% slope is due to the 451 fixed 3/5 ratio of insulin concentration in interstitium (Q) and 452 plasma (I) during steady state. Specifically, ISI is calculated 453 using I and S I is identified using Q.
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The intra-individual CV of S I−MC decreased slightly from 455 CV SI(BEFORE) = 4.6% (90% CI: 3.8-5.9%) to CV SI(AFTER) = 4.3% 456 (90% CI: 3.7-5.2%). A strong correlation of r = 0.83 could be 457 seen between a decrease in insulin sensitivity ISI and intra-458 individual CV in S I−MC . Fig. 6 shows the linear relationships 459 between ISI G and CV SI before and after intervention. A clear 460 reduction in accuracy of estimated S I can be seen in subjects 461 with very low insulin sensitivities.
462
Re-simulating the low intensity test protocol with different 463 doses of glucose and insulin showed a clear dependence of 464 accuracy of the method on the dose employed, as can be seen 465 in Fig. 7 . Administering 5 g glucose and 0.5 U insulin resulted in 466 CV SI = 6.9% (90% CI: 4.9-9.9%). The high dose variant with 20 g 467 glucose and 2 U insulin resulted in a more accurate measure 468 with CV SI = 3.6% (90% CI: 3.0-4.5%), which is very close to the 469 accuracy of ISI. Correlation of CV SI with ISI G was stronger in 470 the low dose protocol (r = 0.90) but showed a weaker linear 471 relationship in the high dose variant (r = 0.46).
472
Simulated hepatic insulin clearance n L and simulated first 473 pass hepatic insulin extraction x were underestimated slightly 474 in the Monte Carlo analysis, by −4.4% (90% CI: −16.5-8.1%) 475 and −2.2% (90% CI: −12.4-7.3%), respectively. Simulated glu-476 cose distribution volume V G was overestimated by 1.7% (90% 477 CI: 0.7-3.5%). 
Discussion
The 
508
Other popular methods, widely used due to their simplicity, 509 are surrogate measures such as the OGTT (measuring the rate 510 of glucose decay after an oral glucose load) and HOMA (based 511 on one fasting glucose and insulin sample). These methods 512 are less correlated to the clamp, as they too measure different 513 effects. In particular, HOMA can be very variable due to a pul-514 satile secretion of insulin [16] and assay inaccuracies, leading 515 to a CV > 10% [17] .
516
The proposed low intensity protocol presented was 517 designed to specifically measure the same effects as the clamp 518 in a much shorter and less intense transient test. Variability 519 is constrained to insulin dependent effects in the periphery, 520 controlled by the insulin sensitivity parameter S I . Modeled S I 521 is lower than clamp ISI, but it does not introduce additional 522 variability. The difference is consistent across all individuals, 523 due to the fixed ratio of steady state plasma (I) and intersti-524 tial (Q) insulin in the model. The model and fitting method 525 employed have been well validated [26, 22] and correlated to 526 clamp data in transient and steady state [31] , resulting in very 527 high correlations (r = 0.97 in transient state, r = 0.99 in steady 528 state) [31] .
529
The proposed method was able to estimate S I with high 530 accuracy, given the assay errors and unmodeled suppression 531 of EGP. CV SI was slightly larger than CV ISI . This larger CV 532 can be expected given the highly dynamic state of the pro-533 posed test. Accuracy decreased drastically by 53% in the lower 534 dose test (5 g glucose, 0.5 U insulin), though accuracy was still 535 better than HOMA. The higher dose test (20 g glucose, 2 U 536 insulin) improved accuracy by 20%. As suppression of EGP was 537 adjusted to the dose accordingly, being higher in the high dose 538 test, the still improved accuracy suggests a strong dependence 539 on the signal to noise ratio of the test, with EGP playing a minor 540 role.
541
In spite of the improved accuracy at higher dose, it is not 542 as practical for a simple clinical test, for a variety of reasons. 543 As IV glucose is commonly available in 50% solution, 20 g 544 requires a 40 ml injection of a very viscous solution, which 545 causes discomfort for the test subject. The 2 U insulin dose 546 also increases risk of hypoglycaemia, particularly in lean sub-547 jects. Finally, an intravenous glucose bolus of 20 g is on the 548 upper physiological range, possibly triggering other glucose 549 regulatory effects not accounted for in this simulation, which 550 could in reality worsen results. The 10 g glucose and 1 U insulin 551 dose is only slightly less accurate, but a lot easier and safer 552 to administer in clinical practice. Mean and range of CV SI 553 are greatly reduced in the step from low to medium dose, 554 whereas the improvement from medium to high dose is not 555 as pronounced any more. This decay is shown in Fig. 8, which 556 illustrates that the medium dose of 10 g glucose and 1 U insulin 557 appears to be the best compromise in practicability, safety and 558 accuracy.
559
A strong negative correlation was seen between a decrease 560 in insulin sensitivity ISI G and CV SI . This correlation was even 561 stronger with the low dose test, but was markedly reduced 562 in the high dose test. The origin of this effect is likely phys-563 iological, as insulin-dependent effects are less dominant in 564 subjects with low insulin sensitivity, leading to a reduced sig-565 judging from the accurate simulation of clinically observed 580 dynamics, it is very likely that the effect described by the 581 model parameter S I is physiological and that insulin sensitiv-582 ity can be estimated with similar accuracy in clinical data. This 583 result is supported by the high correlation between S I and ISI 584 using clamp test data [31] . More specifically, because the pro-585 posed low intensity test was specifically designed to measure 586 the same physiological effect as the clamp using highly cor-587 related models and methods, the test should also be highly 588 correlated to the clamp.
589
Even if the most prominent unmodeled dynamic (suppres-590 sion of EGP) is included in this Monte Carlo analysis, real 591 results could still be affected by other effects not simulated 592 here. Inaccuracies in the simulated test protocol were iden-593 tified in initial trials [23] , i.e. in sample timing and imperfect 594 cannula flushing, or incomplete mixing of glucose and insulin 595 in plasma during the first 10 min. These effects are more 596 likely in a clinical, non-research setting with a simple proto-597 col, where special considerations common in research settings 598 cannot be met. These factors have to be taken into account 599 when designing a robust clinical test. Additional variability 600 could be introduced by less accurate assay methods, especially 601 for insulin and C-peptide. The assays used in this study are 602 run by the authors' collaborating laboratory and are amongst 603 the most accurate methods. Less accurate insulin assays with 604 more cross reactivity to proinsulin are still widely used and 605 could increase the test's variability or introduce a systematic 606 error [65, 66] .
607
Finally, in a simulation setting means are limited and not 608 all noise and physiological dynamics can be accounted for. We 609 have tried to best possibly approximate a real clinical setting, 610 but ongoing pilot studies and a complete clinical validation 611 against the gold-standard clamp test will have to be completed 612 to fully validate these simulation results. (I(t), solid) and in interstitial fluid (Q (t), dashed) .
